Oral premalignant lesions are a useful model for developing chemoprevention trials involving lesions throughout the upper aerodigestive tract (1) . These lesions most often develop in association with exposure to carcinogens, such as tobacco and alcohol, and frequently precede the development of invasive carcinoma (2, 3) . Although early oral premalignant lesions (hyperplasia and mild dysplasia) are particularly responsive to single-agent retinoid therapy (4) (5) (6) (7) (8) , advanced oral premalignant lesions (i.e., moderate to severe dysplasia) are known to be resistant to single-agent retinoid therapy (9, 10) . Since the combination of retinoids and interferons (IFNs) has been shown to have an enhancing effect on the induction of cell differentiation and on the suppression of cell proliferation as seen in preclinical (10) (11) (12) (13) (14) and clinical (15) (16) (17) ) studies, we designed a biochemoprevention study for testing a combination of isotretinoin (13-cis-retinoic acid), IFN-␣, and ␣-tocopherol for advanced premalignant lesions in the head and neck. The mutations in the p53 (also known as TP53) gene and alterations in the p53 protein resulting in its accumulation in cells may play a critical role in tumorigenesis (18) (19) (20) , and both are common in human cancers, including premalignant lesions and cancers of the head and neck region (21) (22) (23) . We conducted a prospective, nonrandomized phase II trial to assess the effect of biochemopreventive therapy on the responsiveness of lesions in the head and neck area, particularly consisting of mild to severe dysplasia in a laryngeal site or moderate to severe dysplasia in the oral cavity, and to compare laboratory findings involving p53 alterations.
All eligible patients received highdose isotretinoin (80 mg/m 2 per day), IFN-␣ (3 million U/m 2 twice a week), and ␣-tocopherol (1200 IU/day) for 12 months, unless the lesions showed progressive disease. The patients were evaluated for clinical and pathologic responses at 6 and 12 months after beginning of therapy. All analyses were based on the outcome observed at 6 months unless otherwise specified. All participants had follow-up examinations without therapy for the following 6 months and then had a final biopsy at 18 months. These tissue samples were analyzed for pathologic response, p53 protein expression, and p53 gene mutations. Pathologic changes in tissue in response to the therapy were consistently evaluated according to the criteria previously described (24) by one pathologist (A. El-Naggar). All pathology slides were coded by numbers, and the pathologist was blinded to the time the biopsies were performed. Immunohistochemical staining was performed on tissue sections by use of monoclonal anti-p53 antibody (clone D07; BioGenex, Inc., San Ramon, CA) (22) . The epithelial layer of each lesion was microdissected in three or four serial sections from each biopsy sample, as described previously (25) . The p53 positivity was stratified as low or high, based on two different sets of cut points, i.e., labeling index (L.I.) of less than 0.2 as low and greater than or equal to 0.2 as high or L.I. of less than 0.1 as low and greater than or equal to 0.1 as high (see Fig. 1 legend) . P values were determined with the use of both sets of cut points. Three separate fragments of the p53 gene encompassing exons 5-9 were amplified from the extracted DNA from these microdissections and directly sequenced, as described previously (26) . The optimal two-stage design by Simon (27) was applied, and a 6-month pathologic response was used as the major end point. The pathologic complete response was described as the complete disappearance of dysplastic cells from the epithelium, and the pathologic partial response was described as a reduction in the degree of dysplasia by at least one degree (i.e., severe to moderate dysplasia). Absence of any response (no response) was described as no pathologic change or a minor change involving focal improvement within the same degree of dysplasia. Progressive disease indicated an increase in the severity of dysplasia by at least one degree (i.e., moderate dysplasia to severe dysplasia) or the development of invasive carcinoma. The standard and target response rates were chosen to be 10% and 30% of all patients, respectively. Both the type I and type II error rates were set at 10%. Associations between categorical variables were determined either by the 2 test or Fisher's exact test. Differences between the two groups with respect to continuous variables, such as the differences in p53 protein expression in relation to pathologic progression in laryngeal lesions and in oral cavity lesions, were compared with the use of the Wilcoxon rank sum test. All statistical tests were two-sided; P values of <.05 were considered to be statistically significant.
From June 1994 through August 1998, 35 eligible patients were assessed. The lesions were evaluated for histologic criteria, p53 protein expression, and p53 gene mutations; the results are described in Table 1 . Four patients (11.4%) had mild dysplasia, 16 (45.7%) had moderate dysplasia, and 15 (42.9%) had severe dysplasia. Twenty-two patients (62.9%) had laryngeal lesions (three had mild dysplasia, 10 had moderate dysplasia, and nine had severe dysplasia), and 13 (37.1%) had oral cavity lesions (one had mild dysplasia, six had moderate dysplasia, and six had severe 
*Underlined case patient numbers indicate the laryngeal lesions. Path ‫ס‬ pathologic response, e.g., D 0 ‫ס‬ no dysplasia; D 1 ‫ס‬ mild dysplasia; D 2 ‫ס‬ moderate dysplasia; D 3 ‫ס‬ severe dysplasia; and CA ‫ס‬ invasive cancer. For p53 gene variant: • ‫ס‬ mutant p53; and ⅙ ‫ס‬ wild-type p53. For p53 protein expression: Ⅲ ‫ס‬ high p53 protein (labeling index ജ0.2) and ᮀ ‫ס‬ low p53 protein (labeling index < 0.2). ND ‫ס‬ not determined. The p53 protein labeling index was calculated as the total number of positively stained (nuclear staining) cells divided by the total number of cells counted and enumerated in the parabasal epithelial layer. When multiple samples were taken at each time point, only matched sites were used to evaluate modulation of p53 expression. †At 21 months, the gene was wild-type with low protein, and pathology was severe dysplasia. ‡p53 gene had double mutations at codon 212 (TTT→TCT) and at splicing site of intron (agG to tgG at +2 position from 5Ј end of intron 5 and exon 6 boundary) in the same tissue.
§p53 gene is deleted at codon 168-174. p53 gene had a mutation at splicing site of intron 9 (Ggt to Gga at −2 position from 3Ј end of intron 9 and exon 8 boundary). To determine whether p53 protein expression was associated with patient response as judged by pathologic evaluation of tissues, we compared posttreatment p53 protein expression of tissue samples obtained from 26 of 27 patients (p53 data were not available for one patient) with the corresponding matched pretreatment tissue samples as shown in Fig. 1 . The p53 protein expression in the baseline samples was low (L. I. <0.2) in 12 (46%) of these 26 patients and was high (L. I. ജ0.2) in 14 (54%). Seven of the 12 patients (10 patients with laryngeal lesions and two with oral cavity lesions) with low p53 expression had achieved complete response, one had partial response, three had severe dysplasia, and one had progressive disease by pathologic evaluation. All seven patients who had achieved complete response had laryngeal lesions, and none had oral cavity lesions. Among the 14 patients (seven with laryngeal lesions and seven with oral cavity lesions) with high p53 expression, only two with laryngeal lesions had achieved complete response by pathologic evaluation. None of the seven patients with oral cavity lesions and with high p53 expression showed either complete response or partial response. Therefore, by pathologic evaluation, the group with low p53 protein expression had a higher rate of complete responses than did the group with high p53 protein expression (P ‫ס‬ .04; Fisher's exact test) at the 6-month assessment. Six of 14 patients (seven with oral lesions and seven with laryngeal lesions) who had high p53 protein expression eventually developed invasive carcinoma. Whereas among the 12 patients whose lesions expressed low levels of p53 protein before therapy and continued to show low expression during the therapy, none developed invasive carcinoma (P ‫ס‬ .02; Fisher's exact test) (Fig. 1) .
We observed mutations in p53 gene in eight of 48 baseline tissue samples or in the baseline samples of seven of 34 patients: three with laryngeal lesions and four with oral cavity lesions. Of 27 patients, six had no follow-up data. Of the remaining 21 patients whose baseline tissue samples expressed wild-type p53 gene, at 6 months, 14 patients maintained the wild-type gene in posttreatment samples, while seven subsequently showed p53 gene mutations in the tissues following treatment. Five of these 14 patients (all with laryngeal lesions), whose baseline tissue samples expressed wild-type p53 gene and whose post-treatment tissue samples maintained wild-type during therapy, achieved complete response by pathologic evaluation. In contrast, among 12 patients (five with oral lesions and seven with laryngeal lesions) whose baseline tissue samples expressed mutant p53 protein together with pathologic responses in patients with oral cavity lesions. Of note, when the L.I. of 0.2 was used as the high/low cutoff value for p53 expression, the group with low p53 expression (L.I. <0.2) had a higher rate of complete response than did the group with high p53 expression (L.I. ജ0.2) (P ‫ס‬ .04; by Fisher's exact test). When the L.I. of 0.1 was used as the cutoff value for p53 expression (low expression is L.I. <0.1; high expression is L.I. ജ0.1), P value of .0009 (by Fisher's exact test) was obtained, suggesting that the low-p53-expression group had an even more statistically significant complete response than the high-p53-expression group. gene or whose post-treatment tissue samples showed an outgrowth into a mutant form of p53 gene during the follow-up period between 6 months after therapy to 18 months after therapy, only one patient expressed wild-type p53 after treatment and then showed complete response by pathologic evaluation (P ‫ס‬ .17; Fisher's exact test). Four of eight baseline tissue samples showing mutations in the p53 gene had high p53 protein expression, and the remaining four had low p53 protein expression. Among 39 of 40 baseline samples (one sample did not have p53 sequencing data) that had wild-type p53 gene expression, 18 (46%) had high p53 protein expression, and 21 (54%) exhibited low p53 protein expression. Therefore, we did not find in this study any direct association between p53 protein expression and p53 gene mutations.
This translational study of biochemoprevention of advanced premalignant lesions in the head and neck region was a biomarker-driven clinical trial involving multiple biopsy specimens of lesions in an attempt to better understand the biologic consequences of response to treatment and resistance to this therapy. Combined treatment with isotretinoin, IFN-␣, and ␣-tocopherol achieved a substantial rate of pathologic responses, particularly in patients with laryngeal lesions. This finding is striking because 88.6% (31 of 35 patients) of the patients' lesions monitored in this study were pathologically advanced premalignant lesions (moderate or severe dysplasia). Therefore, it appears that IFN and retinoids have enhancing effects in this setting, as suggested by preclinical and clinical studies (10) (11) (12) (13) (14) (15) (16) (17) . It is well established that moderately or severely dysplastic lesions have a significantly higher risk of transformation to invasive carcinoma than do early premalignant lesions (28, 29) . In our previous studies using retinoids alone (3, 23) , only a minority of the patients studied presented with moderate or severe dysplasia, and response was predominantly observed in less advanced lesions (1,3) . The degree of responsiveness to treatment in this study, however, depended markedly on disease site. Complete pathologic response occurred exclusively in laryngeal lesions, whereas oral cavity lesions were found to be more resistant to this regimen. This differential responsiveness associated with different sites in the head and neck area may be an important clue for better understanding the underlying pathobiology of tumorigenesis, tumor heterogeneity, and organ specificity of response to therapy, although the exact mechanism should be explored further.
In this study, we document the reappearance of the wild-type p53 gene in post-treatment biopsies from seven patients whose pretreatment tissue samples expressed mutant p53 gene. To the best of our knowledge, these results represent the first demonstration of elimination of clonal cells expressing mutant p53 gene by effective biochemopreventive therapy, which not only produced histologic improvement but also allowed the reappearance of the functional or wild-type p53 gene. On the other hand, new mutations of the p53 gene emerged in the lesions of seven other patients during treatment, and no patients in this group achieved a pathologic complete response. This observation suggests that a subset of clonal cells with p53 mutations emerged during the therapy and may have been resistant and survived this therapy.
Patients with low p53 protein expression in baseline biopsy samples achieved higher level pathologic responses (seven [58%] of 12 patients) than those whose baseline biopsy samples had high p53 expression (two [14%] of 14 patients). By p53 sequence analyses, patients whose pretreatment and post-treatment tissue samples maintained wild-type p53 gene also achieved a high rate of pathologic responses. Retention of p53 function appears to be a critical parameter in cancer treatment (30) . Tumor cell killing by radiation therapy or chemotherapeutic agents has been reported to be an active process of apoptotic cell death (31, 32) . Since apoptotic cell death is mediated by a functional p53 gene in many situations, the effectiveness of a given therapy can hinge on the p53 status (32) . In certain circumstances, the p53 effects may be rendered in indirect ways. Since IFN-␣ has an antiangiogenic activity and its combination with retinoids has an enhancing effect on antiangiogenesis (11, 12) , this combined regimen may shut down vascularization in tumorigenesis and possibly push the dysplastic cells into the apoptotic pathway. Those lesions with p53 functional defects, however, may not undergo apoptotic cell death (30) and may then become resistant to this therapy.
In conclusion, biochemopreventive therapy appears to be highly active in advanced premalignant lesions, particularly those of the larynx. Our study extends the valuable record of translational chemopreventive studies (33, 34) that have incorporated biomarkers, such as p53 and other genetic markers. Taken together, these results demonstrate the critical importance of this translational approach for advancing our understanding of the pathobiologic basis of tumorigenesis and therapeutic outcome and for identifying relevant targets to overcome resistance to an effective biochemopreventive regimen. The results of this single-arm, phase II trial should be confirmed in randomized, placebocontrolled phase III trials in the future.
